Allogene TherapeuticsALLO
Market Cap: $586M
About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Employees: 361
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
49% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 43
24% more call options, than puts
Call options by funds: $392K | Put options by funds: $317K
8% more funds holding
Funds holding: 157 [Q1] → 170 (+13) [Q2]
0.24% more ownership
Funds ownership: 78.87% [Q1] → 79.11% (+0.24%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
35% less capital invested
Capital invested by funds: $596M [Q1] → $385M (-$211M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Robert Burns 45% 1-year accuracy 69 / 154 met price target | 221%upside $9 | Buy Reiterated | 15 Aug 2024 |
Citigroup Samantha Semenkow 39% 1-year accuracy 7 / 18 met price target | 186%upside $8 | Buy Maintained | 9 Aug 2024 |
Truist Securities Asthika Goonewardene 48% 1-year accuracy 12 / 25 met price target | 400%upside $14 | Buy Reiterated | 9 Aug 2024 |
Oppenheimer Matthew Biegler 35% 1-year accuracy 9 / 26 met price target | 293%upside $11 | Outperform Assumed | 8 Aug 2024 |
Canaccord Genuity John Newman 67% 1-year accuracy 14 / 21 met price target | 400%upside $14 | Buy Maintained | 8 Aug 2024 |
Financial journalist opinion
Based on 3 articles about ALLO published over the past 30 days